世界のPD-1抗体薬市場予測 2023年-2029年

【英語タイトル】Global PD-1 Antibody Drug Market Growth 2023-2029

LP Informationが出版した調査資料(LP23DC03156)・商品コード:LP23DC03156
・発行会社(調査会社):LP Information
・発行日:2023年11月
・ページ数:115
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野:医薬品&医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥549,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥823,500見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,098,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界のPD-1抗体薬市場」は、過去の販売実績から2022年の世界のPD-1抗体薬の総販売量を検討し、2023年から2029年の予測されるPD-1抗体薬の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別のPD-1抗体薬の市場規模を掲載し、XXX百万米ドル規模の世界のPD-1抗体薬市場の詳細な分析を提供します。本インサイトレポートは、世界のPD-1抗体薬業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界のPD-1抗体薬市場における各社の独自のポジションをより深く理解するために、PD-1抗体薬製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界のPD-1抗体薬市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。PD-1抗体薬の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000%と予測されています。PD-1抗体薬の中国市場は、2023年から2029年までの年平均000%成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。PD-1抗体薬のヨーロッパ市場は、2023年から2029年にかけて年平均000%成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

PD-1抗体薬の世界主要メーカーとしては、Novartis、 Thermo Fisher、 InvivoGen、 BioVision Inc.、 Abcam、 Bristol-Myers Squibb、 Merck、 Ono Pharmaceutical Co., Ltd、 Eli Lilly、 Chugai Pharmaceutical Co., Ltd、 BeiGene、 AbbVie、 TG Therapeutics, Inc、 Beijing Yiqiao Shenzhou Technology Co., Ltd.、 3SBioなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000%のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別のPD-1抗体薬市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査ではPD-1抗体薬市場をセグメンテーションし、種類別 (ペンブロリズマブ、ニボルマブ、シンディリマブ、トリパリマブ、その他)、用途別 (病院、診療所、その他)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分:ペンブロリズマブ、ニボルマブ、シンディリマブ、トリパリマブ、その他

・用途別区分:病院、診療所、その他

・地域別区分
南北アメリカ(アメリカ、カナダ、メキシコ、ブラジル)
アジア太平洋(中国、日本、韓国、東南アジア、インド、オーストラリア)
ヨーロッパ(ドイツ、フランス、イギリス、イタリア、ロシア)
中東・アフリカ(エジプト、南アフリカ、イスラエル、トルコ、GCC諸国)

【本レポートで扱う主な質問】

・世界のPD-1抗体薬市場の10年間の市場状況・展望は?
・世界および地域別に見たPD-1抗体薬市場成長の要因は何か?
・PD-1抗体薬の市場機会はエンドマーケットの規模によってどのように変化するのか?
・PD-1抗体薬のタイプ別、用途別の内訳は?
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は?

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要:PD-1抗体薬の年間販売量2018-2029、地域別現状・将来分析
・PD-1抗体薬の種類別セグメント:ペンブロリズマブ、ニボルマブ、シンディリマブ、トリパリマブ、その他
・PD-1抗体薬の種類別販売量:2018-2023年の販売量、売上、市場シェア、販売価格
・PD-1抗体薬の用途別セグメント:病院、診療所、その他
・PD-1抗体薬の用途別販売量:2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界のPD-1抗体薬市場
・企業別のグローバルPD-1抗体薬市場データ:2018-2023年の年間販売量、市場シェア
・企業別のPD-1抗体薬の年間売上:2018-2023年の売上、市場シェア
・企業別のPD-1抗体薬販売価格
・主要企業のPD-1抗体薬生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

PD-1抗体薬の地域別レビュー
・地域別のPD-1抗体薬市場規模2018-2023:年間販売量、売上
・主要国別のPD-1抗体薬市場規模2018-2023:年間販売量、売上
・南北アメリカのPD-1抗体薬販売の成長
・アジア太平洋のPD-1抗体薬販売の成長
・ヨーロッパのPD-1抗体薬販売の成長
・中東・アフリカのPD-1抗体薬販売の成長

南北アメリカ市場
・南北アメリカの国別のPD-1抗体薬販売量、売上(2018-2023)
・南北アメリカのPD-1抗体薬の種類別販売量
・南北アメリカのPD-1抗体薬の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別のPD-1抗体薬販売量、売上(2018-2023)
・アジア太平洋のPD-1抗体薬の種類別販売量
・アジア太平洋のPD-1抗体薬の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別のPD-1抗体薬販売量、売上(2018-2023)
・ヨーロッパのPD-1抗体薬の種類別販売量
・ヨーロッパのPD-1抗体薬の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別のPD-1抗体薬販売量、売上(2018-2023)
・中東・アフリカのPD-1抗体薬の種類別販売量
・中東・アフリカのPD-1抗体薬の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・PD-1抗体薬の製造コスト構造分析
・PD-1抗体薬の製造プロセス分析
・PD-1抗体薬の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル:直接販売チャンネル、間接販売チャンネル
・PD-1抗体薬の主要なグローバル販売業者
・PD-1抗体薬の主要なグローバル顧客

地域別のPD-1抗体薬市場予測レビュー
・地域別のPD-1抗体薬市場規模予測(2024-2029)
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・PD-1抗体薬の種類別市場規模予測
・PD-1抗体薬の用途別市場規模予測

主要企業分析
Novartis、 Thermo Fisher、 InvivoGen、 BioVision Inc.、 Abcam、 Bristol-Myers Squibb、 Merck、 Ono Pharmaceutical Co., Ltd、 Eli Lilly、 Chugai Pharmaceutical Co., Ltd、 BeiGene、 AbbVie、 TG Therapeutics, Inc、 Beijing Yiqiao Shenzhou Technology Co., Ltd.、 3SBio
・企業情報
・PD-1抗体薬製品
・PD-1抗体薬販売量、売上、価格、粗利益(2018-2023)
・主要ビジネス概要
・最新動向

調査結果および結論

The global PD-1 Antibody Drug market size is projected to grow from US$ 32280 million in 2022 to US$ 85010 million in 2029; it is expected to grow at a CAGR of 14.8% from 2023 to 2029.
United States market for PD-1 Antibody Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for PD-1 Antibody Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for PD-1 Antibody Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key PD-1 Antibody Drug players cover Novartis, Thermo Fisher, InvivoGen, BioVision Inc., Abcam, Bristol-Myers Squibb, Merck, Ono Pharmaceutical Co., Ltd and Eli Lilly, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
PD-1 is an immune checkpoint inhibitor, which is relatively widely used clinically
LPI (LP Information)’ newest research report, the “PD-1 Antibody Drug Industry Forecast” looks at past sales and reviews total world PD-1 Antibody Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected PD-1 Antibody Drug sales for 2023 through 2029. With PD-1 Antibody Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-1 Antibody Drug industry.
This Insight Report provides a comprehensive analysis of the global PD-1 Antibody Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PD-1 Antibody Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PD-1 Antibody Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-1 Antibody Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-1 Antibody Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of PD-1 Antibody Drug market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Pembrolizumab
Nivolumab
Sindilimab
Toripalimab
Other
Segmentation by application
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Novartis
Thermo Fisher
InvivoGen
BioVision Inc.
Abcam
Bristol-Myers Squibb
Merck
Ono Pharmaceutical Co., Ltd
Eli Lilly
Chugai Pharmaceutical Co., Ltd
BeiGene
AbbVie
TG Therapeutics, Inc
Beijing Yiqiao Shenzhou Technology Co., Ltd.
3SBio
Key Questions Addressed in this Report
What is the 10-year outlook for the global PD-1 Antibody Drug market?
What factors are driving PD-1 Antibody Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do PD-1 Antibody Drug market opportunities vary by end market size?
How does PD-1 Antibody Drug break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global PD-1 Antibody Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for PD-1 Antibody Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for PD-1 Antibody Drug by Country/Region, 2018, 2022 & 2029
2.2 PD-1 Antibody Drug Segment by Type
2.2.1 Pembrolizumab
2.2.2 Nivolumab
2.2.3 Sindilimab
2.2.4 Toripalimab
2.2.5 Other
2.3 PD-1 Antibody Drug Sales by Type
2.3.1 Global PD-1 Antibody Drug Sales Market Share by Type (2018-2023)
2.3.2 Global PD-1 Antibody Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global PD-1 Antibody Drug Sale Price by Type (2018-2023)
2.4 PD-1 Antibody Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 PD-1 Antibody Drug Sales by Application
2.5.1 Global PD-1 Antibody Drug Sale Market Share by Application (2018-2023)
2.5.2 Global PD-1 Antibody Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global PD-1 Antibody Drug Sale Price by Application (2018-2023)
3 Global PD-1 Antibody Drug by Company
3.1 Global PD-1 Antibody Drug Breakdown Data by Company
3.1.1 Global PD-1 Antibody Drug Annual Sales by Company (2018-2023)
3.1.2 Global PD-1 Antibody Drug Sales Market Share by Company (2018-2023)
3.2 Global PD-1 Antibody Drug Annual Revenue by Company (2018-2023)
3.2.1 Global PD-1 Antibody Drug Revenue by Company (2018-2023)
3.2.2 Global PD-1 Antibody Drug Revenue Market Share by Company (2018-2023)
3.3 Global PD-1 Antibody Drug Sale Price by Company
3.4 Key Manufacturers PD-1 Antibody Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PD-1 Antibody Drug Product Location Distribution
3.4.2 Players PD-1 Antibody Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for PD-1 Antibody Drug by Geographic Region
4.1 World Historic PD-1 Antibody Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global PD-1 Antibody Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global PD-1 Antibody Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic PD-1 Antibody Drug Market Size by Country/Region (2018-2023)
4.2.1 Global PD-1 Antibody Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global PD-1 Antibody Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas PD-1 Antibody Drug Sales Growth
4.4 APAC PD-1 Antibody Drug Sales Growth
4.5 Europe PD-1 Antibody Drug Sales Growth
4.6 Middle East & Africa PD-1 Antibody Drug Sales Growth
5 Americas
5.1 Americas PD-1 Antibody Drug Sales by Country
5.1.1 Americas PD-1 Antibody Drug Sales by Country (2018-2023)
5.1.2 Americas PD-1 Antibody Drug Revenue by Country (2018-2023)
5.2 Americas PD-1 Antibody Drug Sales by Type
5.3 Americas PD-1 Antibody Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-1 Antibody Drug Sales by Region
6.1.1 APAC PD-1 Antibody Drug Sales by Region (2018-2023)
6.1.2 APAC PD-1 Antibody Drug Revenue by Region (2018-2023)
6.2 APAC PD-1 Antibody Drug Sales by Type
6.3 APAC PD-1 Antibody Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe PD-1 Antibody Drug by Country
7.1.1 Europe PD-1 Antibody Drug Sales by Country (2018-2023)
7.1.2 Europe PD-1 Antibody Drug Revenue by Country (2018-2023)
7.2 Europe PD-1 Antibody Drug Sales by Type
7.3 Europe PD-1 Antibody Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa PD-1 Antibody Drug by Country
8.1.1 Middle East & Africa PD-1 Antibody Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa PD-1 Antibody Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa PD-1 Antibody Drug Sales by Type
8.3 Middle East & Africa PD-1 Antibody Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PD-1 Antibody Drug
10.3 Manufacturing Process Analysis of PD-1 Antibody Drug
10.4 Industry Chain Structure of PD-1 Antibody Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PD-1 Antibody Drug Distributors
11.3 PD-1 Antibody Drug Customer
12 World Forecast Review for PD-1 Antibody Drug by Geographic Region
12.1 Global PD-1 Antibody Drug Market Size Forecast by Region
12.1.1 Global PD-1 Antibody Drug Forecast by Region (2024-2029)
12.1.2 Global PD-1 Antibody Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global PD-1 Antibody Drug Forecast by Type
12.7 Global PD-1 Antibody Drug Forecast by Application
13 Key Players Analysis
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis PD-1 Antibody Drug Product Portfolios and Specifications
13.1.3 Novartis PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Thermo Fisher
13.2.1 Thermo Fisher Company Information
13.2.2 Thermo Fisher PD-1 Antibody Drug Product Portfolios and Specifications
13.2.3 Thermo Fisher PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Thermo Fisher Main Business Overview
13.2.5 Thermo Fisher Latest Developments
13.3 InvivoGen
13.3.1 InvivoGen Company Information
13.3.2 InvivoGen PD-1 Antibody Drug Product Portfolios and Specifications
13.3.3 InvivoGen PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 InvivoGen Main Business Overview
13.3.5 InvivoGen Latest Developments
13.4 BioVision Inc.
13.4.1 BioVision Inc. Company Information
13.4.2 BioVision Inc. PD-1 Antibody Drug Product Portfolios and Specifications
13.4.3 BioVision Inc. PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 BioVision Inc. Main Business Overview
13.4.5 BioVision Inc. Latest Developments
13.5 Abcam
13.5.1 Abcam Company Information
13.5.2 Abcam PD-1 Antibody Drug Product Portfolios and Specifications
13.5.3 Abcam PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Abcam Main Business Overview
13.5.5 Abcam Latest Developments
13.6 Bristol-Myers Squibb
13.6.1 Bristol-Myers Squibb Company Information
13.6.2 Bristol-Myers Squibb PD-1 Antibody Drug Product Portfolios and Specifications
13.6.3 Bristol-Myers Squibb PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bristol-Myers Squibb Main Business Overview
13.6.5 Bristol-Myers Squibb Latest Developments
13.7 Merck
13.7.1 Merck Company Information
13.7.2 Merck PD-1 Antibody Drug Product Portfolios and Specifications
13.7.3 Merck PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Merck Main Business Overview
13.7.5 Merck Latest Developments
13.8 Ono Pharmaceutical Co., Ltd
13.8.1 Ono Pharmaceutical Co., Ltd Company Information
13.8.2 Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolios and Specifications
13.8.3 Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Ono Pharmaceutical Co., Ltd Main Business Overview
13.8.5 Ono Pharmaceutical Co., Ltd Latest Developments
13.9 Eli Lilly
13.9.1 Eli Lilly Company Information
13.9.2 Eli Lilly PD-1 Antibody Drug Product Portfolios and Specifications
13.9.3 Eli Lilly PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Eli Lilly Main Business Overview
13.9.5 Eli Lilly Latest Developments
13.10 Chugai Pharmaceutical Co., Ltd
13.10.1 Chugai Pharmaceutical Co., Ltd Company Information
13.10.2 Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolios and Specifications
13.10.3 Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Chugai Pharmaceutical Co., Ltd Main Business Overview
13.10.5 Chugai Pharmaceutical Co., Ltd Latest Developments
13.11 BeiGene
13.11.1 BeiGene Company Information
13.11.2 BeiGene PD-1 Antibody Drug Product Portfolios and Specifications
13.11.3 BeiGene PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 BeiGene Main Business Overview
13.11.5 BeiGene Latest Developments
13.12 AbbVie
13.12.1 AbbVie Company Information
13.12.2 AbbVie PD-1 Antibody Drug Product Portfolios and Specifications
13.12.3 AbbVie PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 AbbVie Main Business Overview
13.12.5 AbbVie Latest Developments
13.13 TG Therapeutics, Inc
13.13.1 TG Therapeutics, Inc Company Information
13.13.2 TG Therapeutics, Inc PD-1 Antibody Drug Product Portfolios and Specifications
13.13.3 TG Therapeutics, Inc PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 TG Therapeutics, Inc Main Business Overview
13.13.5 TG Therapeutics, Inc Latest Developments
13.14 Beijing Yiqiao Shenzhou Technology Co., Ltd.
13.14.1 Beijing Yiqiao Shenzhou Technology Co., Ltd. Company Information
13.14.2 Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Product Portfolios and Specifications
13.14.3 Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Beijing Yiqiao Shenzhou Technology Co., Ltd. Main Business Overview
13.14.5 Beijing Yiqiao Shenzhou Technology Co., Ltd. Latest Developments
13.15 3SBio
13.15.1 3SBio Company Information
13.15.2 3SBio PD-1 Antibody Drug Product Portfolios and Specifications
13.15.3 3SBio PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 3SBio Main Business Overview
13.15.5 3SBio Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. PD-1 Antibody Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. PD-1 Antibody Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Pembrolizumab
Table 4. Major Players of Nivolumab
Table 5. Major Players of Sindilimab
Table 6. Major Players of Toripalimab
Table 7. Major Players of Other
Table 8. Global PD-1 Antibody Drug Sales by Type (2018-2023) & (K Units)
Table 9. Global PD-1 Antibody Drug Sales Market Share by Type (2018-2023)
Table 10. Global PD-1 Antibody Drug Revenue by Type (2018-2023) & ($ million)
Table 11. Global PD-1 Antibody Drug Revenue Market Share by Type (2018-2023)
Table 12. Global PD-1 Antibody Drug Sale Price by Type (2018-2023) & (US$/Unit)
Table 13. Global PD-1 Antibody Drug Sales by Application (2018-2023) & (K Units)
Table 14. Global PD-1 Antibody Drug Sales Market Share by Application (2018-2023)
Table 15. Global PD-1 Antibody Drug Revenue by Application (2018-2023)
Table 16. Global PD-1 Antibody Drug Revenue Market Share by Application (2018-2023)
Table 17. Global PD-1 Antibody Drug Sale Price by Application (2018-2023) & (US$/Unit)
Table 18. Global PD-1 Antibody Drug Sales by Company (2018-2023) & (K Units)
Table 19. Global PD-1 Antibody Drug Sales Market Share by Company (2018-2023)
Table 20. Global PD-1 Antibody Drug Revenue by Company (2018-2023) ($ Millions)
Table 21. Global PD-1 Antibody Drug Revenue Market Share by Company (2018-2023)
Table 22. Global PD-1 Antibody Drug Sale Price by Company (2018-2023) & (US$/Unit)
Table 23. Key Manufacturers PD-1 Antibody Drug Producing Area Distribution and Sales Area
Table 24. Players PD-1 Antibody Drug Products Offered
Table 25. PD-1 Antibody Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global PD-1 Antibody Drug Sales by Geographic Region (2018-2023) & (K Units)
Table 29. Global PD-1 Antibody Drug Sales Market Share Geographic Region (2018-2023)
Table 30. Global PD-1 Antibody Drug Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global PD-1 Antibody Drug Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global PD-1 Antibody Drug Sales by Country/Region (2018-2023) & (K Units)
Table 33. Global PD-1 Antibody Drug Sales Market Share by Country/Region (2018-2023)
Table 34. Global PD-1 Antibody Drug Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global PD-1 Antibody Drug Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas PD-1 Antibody Drug Sales by Country (2018-2023) & (K Units)
Table 37. Americas PD-1 Antibody Drug Sales Market Share by Country (2018-2023)
Table 38. Americas PD-1 Antibody Drug Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas PD-1 Antibody Drug Revenue Market Share by Country (2018-2023)
Table 40. Americas PD-1 Antibody Drug Sales by Type (2018-2023) & (K Units)
Table 41. Americas PD-1 Antibody Drug Sales by Application (2018-2023) & (K Units)
Table 42. APAC PD-1 Antibody Drug Sales by Region (2018-2023) & (K Units)
Table 43. APAC PD-1 Antibody Drug Sales Market Share by Region (2018-2023)
Table 44. APAC PD-1 Antibody Drug Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC PD-1 Antibody Drug Revenue Market Share by Region (2018-2023)
Table 46. APAC PD-1 Antibody Drug Sales by Type (2018-2023) & (K Units)
Table 47. APAC PD-1 Antibody Drug Sales by Application (2018-2023) & (K Units)
Table 48. Europe PD-1 Antibody Drug Sales by Country (2018-2023) & (K Units)
Table 49. Europe PD-1 Antibody Drug Sales Market Share by Country (2018-2023)
Table 50. Europe PD-1 Antibody Drug Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe PD-1 Antibody Drug Revenue Market Share by Country (2018-2023)
Table 52. Europe PD-1 Antibody Drug Sales by Type (2018-2023) & (K Units)
Table 53. Europe PD-1 Antibody Drug Sales by Application (2018-2023) & (K Units)
Table 54. Middle East & Africa PD-1 Antibody Drug Sales by Country (2018-2023) & (K Units)
Table 55. Middle East & Africa PD-1 Antibody Drug Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa PD-1 Antibody Drug Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa PD-1 Antibody Drug Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa PD-1 Antibody Drug Sales by Type (2018-2023) & (K Units)
Table 59. Middle East & Africa PD-1 Antibody Drug Sales by Application (2018-2023) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of PD-1 Antibody Drug
Table 61. Key Market Challenges & Risks of PD-1 Antibody Drug
Table 62. Key Industry Trends of PD-1 Antibody Drug
Table 63. PD-1 Antibody Drug Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. PD-1 Antibody Drug Distributors List
Table 66. PD-1 Antibody Drug Customer List
Table 67. Global PD-1 Antibody Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 68. Global PD-1 Antibody Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas PD-1 Antibody Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 70. Americas PD-1 Antibody Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC PD-1 Antibody Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 72. APAC PD-1 Antibody Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe PD-1 Antibody Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Europe PD-1 Antibody Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa PD-1 Antibody Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Middle East & Africa PD-1 Antibody Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global PD-1 Antibody Drug Sales Forecast by Type (2024-2029) & (K Units)
Table 78. Global PD-1 Antibody Drug Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global PD-1 Antibody Drug Sales Forecast by Application (2024-2029) & (K Units)
Table 80. Global PD-1 Antibody Drug Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. Novartis Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 82. Novartis PD-1 Antibody Drug Product Portfolios and Specifications
Table 83. Novartis PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 84. Novartis Main Business
Table 85. Novartis Latest Developments
Table 86. Thermo Fisher Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 87. Thermo Fisher PD-1 Antibody Drug Product Portfolios and Specifications
Table 88. Thermo Fisher PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 89. Thermo Fisher Main Business
Table 90. Thermo Fisher Latest Developments
Table 91. InvivoGen Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 92. InvivoGen PD-1 Antibody Drug Product Portfolios and Specifications
Table 93. InvivoGen PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 94. InvivoGen Main Business
Table 95. InvivoGen Latest Developments
Table 96. BioVision Inc. Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 97. BioVision Inc. PD-1 Antibody Drug Product Portfolios and Specifications
Table 98. BioVision Inc. PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 99. BioVision Inc. Main Business
Table 100. BioVision Inc. Latest Developments
Table 101. Abcam Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 102. Abcam PD-1 Antibody Drug Product Portfolios and Specifications
Table 103. Abcam PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 104. Abcam Main Business
Table 105. Abcam Latest Developments
Table 106. Bristol-Myers Squibb Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 107. Bristol-Myers Squibb PD-1 Antibody Drug Product Portfolios and Specifications
Table 108. Bristol-Myers Squibb PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 109. Bristol-Myers Squibb Main Business
Table 110. Bristol-Myers Squibb Latest Developments
Table 111. Merck Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 112. Merck PD-1 Antibody Drug Product Portfolios and Specifications
Table 113. Merck PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 114. Merck Main Business
Table 115. Merck Latest Developments
Table 116. Ono Pharmaceutical Co., Ltd Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 117. Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolios and Specifications
Table 118. Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 119. Ono Pharmaceutical Co., Ltd Main Business
Table 120. Ono Pharmaceutical Co., Ltd Latest Developments
Table 121. Eli Lilly Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 122. Eli Lilly PD-1 Antibody Drug Product Portfolios and Specifications
Table 123. Eli Lilly PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 124. Eli Lilly Main Business
Table 125. Eli Lilly Latest Developments
Table 126. Chugai Pharmaceutical Co., Ltd Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 127. Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolios and Specifications
Table 128. Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 129. Chugai Pharmaceutical Co., Ltd Main Business
Table 130. Chugai Pharmaceutical Co., Ltd Latest Developments
Table 131. BeiGene Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 132. BeiGene PD-1 Antibody Drug Product Portfolios and Specifications
Table 133. BeiGene PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 134. BeiGene Main Business
Table 135. BeiGene Latest Developments
Table 136. AbbVie Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 137. AbbVie PD-1 Antibody Drug Product Portfolios and Specifications
Table 138. AbbVie PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 139. AbbVie Main Business
Table 140. AbbVie Latest Developments
Table 141. TG Therapeutics, Inc Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 142. TG Therapeutics, Inc PD-1 Antibody Drug Product Portfolios and Specifications
Table 143. TG Therapeutics, Inc PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 144. TG Therapeutics, Inc Main Business
Table 145. TG Therapeutics, Inc Latest Developments
Table 146. Beijing Yiqiao Shenzhou Technology Co., Ltd. Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 147. Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Product Portfolios and Specifications
Table 148. Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 149. Beijing Yiqiao Shenzhou Technology Co., Ltd. Main Business
Table 150. Beijing Yiqiao Shenzhou Technology Co., Ltd. Latest Developments
Table 151. 3SBio Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 152. 3SBio PD-1 Antibody Drug Product Portfolios and Specifications
Table 153. 3SBio PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 154. 3SBio Main Business
Table 155. 3SBio Latest Developments
List of Figures
Figure 1. Picture of PD-1 Antibody Drug
Figure 2. PD-1 Antibody Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PD-1 Antibody Drug Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global PD-1 Antibody Drug Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. PD-1 Antibody Drug Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Pembrolizumab
Figure 10. Product Picture of Nivolumab
Figure 11. Product Picture of Sindilimab
Figure 12. Product Picture of Toripalimab
Figure 13. Product Picture of Other
Figure 14. Global PD-1 Antibody Drug Sales Market Share by Type in 2022
Figure 15. Global PD-1 Antibody Drug Revenue Market Share by Type (2018-2023)
Figure 16. PD-1 Antibody Drug Consumed in Hospital
Figure 17. Global PD-1 Antibody Drug Market: Hospital (2018-2023) & (K Units)
Figure 18. PD-1 Antibody Drug Consumed in Clinic
Figure 19. Global PD-1 Antibody Drug Market: Clinic (2018-2023) & (K Units)
Figure 20. PD-1 Antibody Drug Consumed in Other
Figure 21. Global PD-1 Antibody Drug Market: Other (2018-2023) & (K Units)
Figure 22. Global PD-1 Antibody Drug Sales Market Share by Application (2022)
Figure 23. Global PD-1 Antibody Drug Revenue Market Share by Application in 2022
Figure 24. PD-1 Antibody Drug Sales Market by Company in 2022 (K Units)
Figure 25. Global PD-1 Antibody Drug Sales Market Share by Company in 2022
Figure 26. PD-1 Antibody Drug Revenue Market by Company in 2022 ($ Million)
Figure 27. Global PD-1 Antibody Drug Revenue Market Share by Company in 2022
Figure 28. Global PD-1 Antibody Drug Sales Market Share by Geographic Region (2018-2023)
Figure 29. Global PD-1 Antibody Drug Revenue Market Share by Geographic Region in 2022
Figure 30. Americas PD-1 Antibody Drug Sales 2018-2023 (K Units)
Figure 31. Americas PD-1 Antibody Drug Revenue 2018-2023 ($ Millions)
Figure 32. APAC PD-1 Antibody Drug Sales 2018-2023 (K Units)
Figure 33. APAC PD-1 Antibody Drug Revenue 2018-2023 ($ Millions)
Figure 34. Europe PD-1 Antibody Drug Sales 2018-2023 (K Units)
Figure 35. Europe PD-1 Antibody Drug Revenue 2018-2023 ($ Millions)
Figure 36. Middle East & Africa PD-1 Antibody Drug Sales 2018-2023 (K Units)
Figure 37. Middle East & Africa PD-1 Antibody Drug Revenue 2018-2023 ($ Millions)
Figure 38. Americas PD-1 Antibody Drug Sales Market Share by Country in 2022
Figure 39. Americas PD-1 Antibody Drug Revenue Market Share by Country in 2022
Figure 40. Americas PD-1 Antibody Drug Sales Market Share by Type (2018-2023)
Figure 41. Americas PD-1 Antibody Drug Sales Market Share by Application (2018-2023)
Figure 42. United States PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 43. Canada PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 44. Mexico PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 45. Brazil PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 46. APAC PD-1 Antibody Drug Sales Market Share by Region in 2022
Figure 47. APAC PD-1 Antibody Drug Revenue Market Share by Regions in 2022
Figure 48. APAC PD-1 Antibody Drug Sales Market Share by Type (2018-2023)
Figure 49. APAC PD-1 Antibody Drug Sales Market Share by Application (2018-2023)
Figure 50. China PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 51. Japan PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 52. South Korea PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 53. Southeast Asia PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 54. India PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 55. Australia PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 56. China Taiwan PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 57. Europe PD-1 Antibody Drug Sales Market Share by Country in 2022
Figure 58. Europe PD-1 Antibody Drug Revenue Market Share by Country in 2022
Figure 59. Europe PD-1 Antibody Drug Sales Market Share by Type (2018-2023)
Figure 60. Europe PD-1 Antibody Drug Sales Market Share by Application (2018-2023)
Figure 61. Germany PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 62. France PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 63. UK PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 64. Italy PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 65. Russia PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 66. Middle East & Africa PD-1 Antibody Drug Sales Market Share by Country in 2022
Figure 67. Middle East & Africa PD-1 Antibody Drug Revenue Market Share by Country in 2022
Figure 68. Middle East & Africa PD-1 Antibody Drug Sales Market Share by Type (2018-2023)
Figure 69. Middle East & Africa PD-1 Antibody Drug Sales Market Share by Application (2018-2023)
Figure 70. Egypt PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 71. South Africa PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 72. Israel PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 73. Turkey PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 74. GCC Country PD-1 Antibody Drug Revenue Growth 2018-2023 ($ Millions)
Figure 75. Manufacturing Cost Structure Analysis of PD-1 Antibody Drug in 2022
Figure 76. Manufacturing Process Analysis of PD-1 Antibody Drug
Figure 77. Industry Chain Structure of PD-1 Antibody Drug
Figure 78. Channels of Distribution
Figure 79. Global PD-1 Antibody Drug Sales Market Forecast by Region (2024-2029)
Figure 80. Global PD-1 Antibody Drug Revenue Market Share Forecast by Region (2024-2029)
Figure 81. Global PD-1 Antibody Drug Sales Market Share Forecast by Type (2024-2029)
Figure 82. Global PD-1 Antibody Drug Revenue Market Share Forecast by Type (2024-2029)
Figure 83. Global PD-1 Antibody Drug Sales Market Share Forecast by Application (2024-2029)
Figure 84. Global PD-1 Antibody Drug Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界のPD-1抗体薬市場予測 2023年-2029年] (コード:LP23DC03156)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のPD-1抗体薬市場予測 2023年-2029年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆